To investigate the role of pLIRTAC in advancing targeted protein degradation (TPD) in glioma and CAR-T cell therapy.
Analyzed the effects of pLIRTAC on protein degradation in glioma cells.
Assessed the therapeutic implications of TPD technology in CAR-T cell therapy.
pLIRTAC effectively controls abnormal proteins in glioma cells.
Study indicates potential for expanding TPD applications in immune therapies like CAR-T.
Abstract
, providing a robust and effective tool for the control of endogenous abnormal proteins in cells, and can potentially further expand the therapeutic application of TPD technology.